Aragen in vitro/ex vivo services can be applied to large and small molecule therapeutics, as well as nucleic acid and stem cell therapeutics. We understand the need for flexibility and attention to detail in all our solutions offerings, and our experienced assay development scientists work closely with our clients on custom projects, creating novel assays that meet their research requirements.
In Vitro Assays
Ex Vivo Assays
Pseudovirus System for SARS-CoV-2
The vesicular stomatitis virus (VSV)-based pseudovirus system incorporating the Spike protein from SARS-CoV-2 is a useful tool for the analysis of serum from vaccine studies, monoclonal antibodies or therapeutics that impact the entry of SARS-CoV-2 into cells. In this system, the VSV genome has been modified to eliminate the expression of its attachment/fusion protein (G protein). The attachment/fusion proteins from heterologous viruses can then be expressed from a plasmid during an infection with the modified VSV. The emerging virus particles contain a functional SARS-CoV-2 Spike protein on the surface of the VSV. This system can be quickly updated with emerging original SARS-COV-2 as well as the variants on the Spike protein. Experts in virology perform these assays in BSL2 laboratories.
A diverse portfolio of cell-based and biophysical assays that enable the development and characterization of new therapeutics.
Rodent PK (in life) studies conducted in AAALAC accredited, state-of-the-art facilities.
Different animal protocols, optimized planning, and experimental design to accelerate research programs.
